Log in

NASDAQ:IARTIntegra Lifesciences Stock Price, Forecast & News

$48.72
+0.07 (+0.14 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$48.60
Now: $48.72
$49.81
50-Day Range
$45.60
MA: $49.73
$55.57
52-Week Range
$34.21
Now: $48.72
$65.09
Volume526,759 shs
Average Volume624,110 shs
Market Capitalization$4.13 billion
P/E Ratio157.16
Dividend YieldN/A
Beta1.09
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, Asia Pacific, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Read More
Integra Lifesciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.68 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 billion
Cash Flow$4.10 per share
Book Value$16.50 per share

Profitability

Net Income$50.20 million

Miscellaneous

Employees4,000
Market Cap$4.13 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableOptionable

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

How has Integra Lifesciences' stock been impacted by COVID-19 (Coronavirus)?

Integra Lifesciences' stock was trading at $46.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IART shares have increased by 5.7% and is now trading at $48.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Integra Lifesciences?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Integra Lifesciences.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Integra Lifesciences.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) announced its earnings results on Thursday, May, 7th. The life sciences company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.63 by $0.15. The life sciences company had revenue of $354.30 million for the quarter, compared to analysts' expectations of $353.15 million. Integra Lifesciences had a return on equity of 15.98% and a net margin of 1.76%. The firm's revenue was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.65 earnings per share. View Integra Lifesciences' earnings history.

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Shares of Integra Lifesciences split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were issued to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences updated its first quarter 2020 After-Hours earnings guidance on Tuesday, April, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $352-354 million, compared to the consensus revenue estimate of $367.38 million.

What price target have analysts set for IART?

11 equities research analysts have issued 12 month target prices for Integra Lifesciences' stock. Their forecasts range from $46.00 to $68.00. On average, they anticipate Integra Lifesciences' share price to reach $58.00 in the next twelve months. This suggests a possible upside of 19.0% from the stock's current price. View analysts' price targets for Integra Lifesciences.

Has Integra Lifesciences been receiving favorable news coverage?

News articles about IART stock have been trending negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Integra Lifesciences earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned news headlines about the life sciences company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Integra Lifesciences.

Are investors shorting Integra Lifesciences?

Integra Lifesciences saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 3,690,000 shares, an increase of 16.8% from the May 31st total of 3,160,000 shares. Based on an average daily trading volume, of 670,800 shares, the days-to-cover ratio is presently 5.5 days. Currently, 5.2% of the shares of the company are sold short. View Integra Lifesciences' Current Options Chain.

Who are some of Integra Lifesciences' key competitors?

What other stocks do shareholders of Integra Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Boeing (BA), Applied Materials (AMAT) and Celgene (CELG).

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the following people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $48.72.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $4.13 billion and generates $1.52 billion in revenue each year. The life sciences company earns $50.20 million in net income (profit) each year or $2.74 on an earnings per share basis. Integra Lifesciences employs 4,000 workers across the globe.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is www.integralife.com.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.